Evidence map›Paper›PMID 31885471›Full record

ReviewSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2019

Thymoquinone (2-Isoprpyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/anticancer agent: Chemistry and biological effects.

Anas Ahmad, Rakesh Kumar Mishra, Akshay Vyawahare, Ajay Kumar, Muneeb U Rehman, Wajhul Qamar, Abdul Quaiyoom Khan, Rehan Khan

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
23.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 156 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Analysis of Pharmacological Properties ofLife (Basel, Switzerland) · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Anas AhmadDepartment of Nano-Therapeutics, Institute of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali, Punjab 160062, India.
Rakesh Kumar MishraDepartment of Nano-Therapeutics, Institute of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali, Punjab 160062, India.
Akshay VyawahareDepartment of Nano-Therapeutics, Institute of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali, Punjab 160062, India.
Ajay KumarDepartment of Nano-Therapeutics, Institute of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali, Punjab 160062, India.
Muneeb U RehmanDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Wajhul QamarDepartment of Pharmacology and Toxicology, College of pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Abdul Quaiyoom KhanTranslational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
Rehan KhanDepartment of Nano-Therapeutics, Institute of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali, Punjab 160062, India.
India Habitat Centre · INInstitute of Nano Science and TechnologyKing Saud University · SAHamad Medical Corporation · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains the topmost disorders of the mankind and number of cases is unceasingly growing at unprecedented rates. Although the synthetic anti-cancer compounds still hold the largest market in the modern treatment of cancer, natural agents have always been tried and tested for potential anti-cancer properties. Thymoquinone (TQ), a monoterpene and main ingredient in the essential oil of

Indexed as

AMPK, AMP-activated protein kinaseAnti-cancer therapeuticsAPC, adenomatous polyposis coliCDDP, cisplatinCDKs, cyclin-dependent kinaseseEF-2K, elongation factor 2 kinaseEMT, epithelial to mesenchymal transitionFGFs, fibroblast growth factorsFTIR, fourier-transform infrared spectroscopyGBM, glioblastoma multiformeHPDE, human pancreatic ductal epithelial cellsIUPAC, international union of pure and applied chemistryLKB1, liver kinase B1LPS, lipopolysaccharideMC-A, myrtucommulone-ANatural compoundsNLCs, nanostructured lipid carriersNMR, nuclear magnetic resonanceNSAIDs, non-steroidal anti-inflammatory drugsOEC, oral epithelial cellsPCNA, proliferating cell nuclear antigenPhytopharmaceuticalsPlant productsPXRD, powder x-ray diffractionRES, resveratrolRNS, reactive nitrogen speciesROS, reactive oxygen speciesSCLC, small cell lung carcinomaSLNs, solid lipid nanoparticlesTHQ, thymohydroquinoneThymoquinoneTMZ, temozolomideTNBC, triple negative breast cancerTNFα, tumor necrosis factor alphaTQ, thymoquinoneUMSCC, university of Michigan squamous cell carcinomaUSD, United States DollarVEGF, vascular endothelial growth factorWHO, world health organizationXIAP, X-linked inhibitor of apoptosis protein

Identifiers

PMID31885471
PMCPMC6921197
OpenAlexW2976920938

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.